CompletedPhase 3

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

United States114 participantsStarted 2022-11-23

Plain-language summary

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Proptosis ≥ 18 mm and/or
✓. Proptosis ≥ 3 mm increase from participant's baseline (prior to diagnosis of TED), as estimated by the Investigator/assessor

What they're measuring

Percentage of proptosis responders

Timeframe: At Week 24

Trial details

NCT IDNCT05517421

SponsorImmunovant Sciences GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-11-02

View on ClinicalTrials.gov More Thyroid Eye Disease trials